An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

Description

This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.

Conditions

Hepatic Impairment

Talk to us

Study Overview

On this page

Study Details

Study overview

This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.

A Phase 1, Open Label, Single Dose Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of ESK001

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

Condition
Hepatic Impairment
Intervention / Treatment

-

Contacts and Locations

Lake Forest

Orange County Research Center, Lake Forest, California, United States, 92630

Miami Lakes

Panax Clinical Research, Miami Lakes, Florida, United States, 33104

Orlando

Orlando Clinical Research Center, Orlando, Florida, United States, 32809

Knoxville

Alliance for Multispecialty Research, Knoxville, Tennessee, United States, 37920

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to 75 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    Yes

    Collaborators and Investigators

    Alumis Inc,

    Jorn Drappa, Medical Director, STUDY_DIRECTOR, Alumis Inc

    Study Record Dates

    2025-12